Association between myelofibrosis and thromboembolism: A population‐based retrospective cohort study

The risk of thromboembolism in myelofibrosis remains incompletely understood.

[1]  N. Gronich,et al.  Association of Diabetes and Glycated Hemoglobin With the Risk of Intracerebral Hemorrhage: A Population-Based Cohort Study , 2019, Diabetes Care.

[2]  S. Verstovsek,et al.  The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review , 2017, Annals of Hematology.

[3]  G. Rennert,et al.  Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. , 2017, Blood.

[4]  A. Tefferi,et al.  Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management , 2016 .

[5]  M. Griesshammer,et al.  Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients , 2016, Blood Cancer Journal.

[6]  S. Vesely,et al.  The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis , 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[7]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[8]  T. Brümmendorf,et al.  Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry , 2016, Journal of Hematology & Oncology.

[9]  Jason P. Fine,et al.  Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .

[10]  A. Zizzi,et al.  Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis , 2015, Diagnostic Pathology.

[11]  M. Michalak,et al.  The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. , 2015, Thrombosis research.

[12]  E. Mathiesen,et al.  Atrial fibrillation and future risk of venous thromboembolism:the Tromsø study , 2015, Journal of thrombosis and haemostasis : JTH.

[13]  F. Sung,et al.  Atrial fibrillation associated with increased risk of venous thromboembolism , 2014, Thrombosis and Haemostasis.

[14]  D. Valla,et al.  Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. , 2012, Blood.

[15]  T. Barbui,et al.  Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients , 2012, American journal of hematology.

[16]  G. Barosi,et al.  Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis , 2012, PloS one.

[17]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[18]  A. Tefferi,et al.  Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked , 2010, Haematologica.

[19]  T. Barbui,et al.  Thrombosis in primary myelofibrosis: incidence and risk factors. , 2009, Blood.

[20]  H. Büller,et al.  Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. , 2009, Thrombosis research.

[21]  J. Avorn,et al.  High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data , 2009, Epidemiology.

[22]  T. Schiano,et al.  The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. , 2009, Blood.

[23]  N. Villamor,et al.  Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis , 2008, Annals of Hematology.

[24]  W. Aird.  Vascular bed‐specific thrombosis , 2007, Journal of thrombosis and haemostasis : JTH.

[25]  R. Landolfi,et al.  Efficacy and safety of low-dose aspirin in polycythemia vera , 2004 .

[26]  T. Barbui,et al.  Efficacy and safety of low-dose aspirin in polycythemia vera. , 2004, The New England journal of medicine.

[27]  T. Barbui,et al.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. , 1995, The New England journal of medicine.

[28]  E. Montserrat,et al.  Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution , 2006, Leukemia.